Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India

2021 ◽  
Author(s):  
Lalatendu Moharana ◽  
Lokanatha Dasappa ◽  
Suresh Babu ◽  
K. N. Lokesh ◽  
Ah Rudresh ◽  
...  
Keyword(s):  
Retrospective Study ◽  
B Cell ◽  
South India ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Not Otherwise Specified ◽  
Cancer Hospital

scholarly journals Double-hit lymphoma: optimizing therapy

Hematology ◽  
2021 ◽  
Vol 2021 (1) ◽  
pp. 157-163
Author(s):  
Kieron Dunleavy
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Multicenter Studies ◽  
Not Otherwise Specified ◽  
Double Hit Lymphoma ◽  
Genomic Studies ◽  
Novel Approaches ◽  
Poor Outcomes

Abstract Aggressive B-cell lymphoma is a heterogeneous entity with disparate outcomes based on clinical and pathological characteristics. While most tumors in this category are diffuse large B-cell lymphoma (DLBCL), the recognition that some cases have high-grade morphology and frequently harbor MYC and BCL2 and/or BCL6 translocations has led to their separate categorization. These cases are now considered distinct from DLBCL and are named “high-grade B-cell lymphoma” (HGBL). Most are characterized by distinct rearrangements, but others have high-grade morphological features without these and are called HGBL-not otherwise specified. Studies have demonstrated that this group of diseases leads to poor outcomes following standard rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy; retrospective and recent single-arm, multicenter studies suggest they should be approached with dose-intense treatment platforms. As yet, this has not been validated in randomized trial settings due to the rarity of these diseases. In the relapsed and refractory setting, novel approaches such as anti-CD19 chimeric antigen receptor T cells and antibodies against CD19 have demonstrated high efficacy in this subgroup. Recently, genomic studies have made much progress in investigating some of the molecular underpinnings that drive their lymphomagenesis and have paved the way for testing additional novel approaches.

Diffuse large B-cell lymphoma: A retrospective study from a regional care center in South India

2018 ◽  
Vol 55 (1) ◽  
pp. 66 ◽  
Author(s):  
SuparnaAjit Rao ◽  
SureshMC Babu ◽  
Sunny Garg ◽  
GovindaBabu Kanakasetty ◽  
LakshmaiahChinnagiriyappa Kuntegowdanahalli ◽  
...  
Keyword(s):  
Retrospective Study ◽  
B Cell ◽  
South India ◽  
Cell Lymphoma ◽  
Care Center ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Tumor necrosis factor- and interleukin-6-producing high-grade B-cell lymphoma, not otherwise specified in the pleura

2018 ◽  
Vol 10 ◽  
pp. 1-3 ◽  
Author(s):  
Shoko Nakayama ◽  
Mitsuhiro Matsuda ◽  
Tatsuya Adachi ◽  
Sanae Sueda ◽  
Kayo Ueda ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
B Cell ◽  
Interleukin 6 ◽  
Tumor Necrosis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Not Otherwise Specified ◽  
Necrosis Factor

Does CNS Prophylaxis Prevent CNS Relapse in Patients with High-Grade B-Cell Lymphoma Double-Hit and not Otherwise Specified?

2019 ◽  
Vol 19 ◽  
pp. S254-S255
Author(s):  
Anna Misyurina ◽  
Sergey Kravchenko ◽  
Aminat Magomedova ◽  
Yana Mangasarova ◽  
Elena Baryakh ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Cns Prophylaxis ◽  
Not Otherwise Specified ◽  
Cns Relapse ◽  
Double Hit

scholarly journals A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival

Hematology ◽  
2020 ◽  
Vol 25 (1) ◽  
pp. 203-210
Author(s):  
Tingting Zhang ◽  
Hongguo Zhao ◽  
Zhongguang Cui ◽  
Haicang Xu ◽  
Xiaodan Liu ◽  
...  
Keyword(s):  
Retrospective Study ◽  
B Cell ◽  
Cell Lymphoma ◽  
Treatment Strategies ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Lymphoma Treatment ◽  
Large B Cell ◽  
Multicentre Retrospective Study

scholarly journals High-Grade B-Cell Lymphoma Not Otherwise Specified (HGBL, NOS) in the Maxillary Sinus Mimicking Periapical Inflammation: Case Report and Review of the Literature

2021 ◽  
Vol 11 (19) ◽  
pp. 8803
Author(s):  
Andrea Brody ◽  
Csaba Dobo-Nagy ◽  
Karoly Mensch ◽  
Zsuzsanna Oltyan ◽  
Judit Csomor ◽  
...  
Keyword(s):  
B Cell ◽  
Maxillary Sinus ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Grade ◽  
B Cell Lymphomas ◽  
Not Otherwise Specified ◽  
Systemic Spread ◽  
Periapical Inflammation

High-grade B-cell lymphoma not otherwise specified is listed as a new group in the WHO 2017 statement as a subtype of aggressive, mature B-cell lymphomas with a poor prognosis. To our knowledge, no description of this genetic type of maxillary lymphoma has appeared in the literature until now; thus, our case provides valuable data on its symptoms, clinical behavior, response to treatment and survival rate. The present report describes the early diagnosis and treatment of an extremely rare histological subtype of B-cell lymphoma, a case of high-grade B-cell lymphoma not otherwise specified, localized in the maxillary sinus and mimicking signs and symptoms of periapical inflammation. After chemotherapy, the presented patient showed complete remission without relapse and systemic spread. As far as we know, this is the first reported case of this rare type of lymphoma associated with the maxillary sinus. Considering that high-grade B-cell lymphomas are aggressive tumors with rapid growth and poor prognosis, which are often misdiagnosed in the early stages as inflammatory disease, it is relevant to highlight the importance of a detailed evaluation of clinical signs and radiological findings during diagnosis, especially if they contradict each other.

Sign in / Sign up

Export Citation Format

Share Document